The world needs rapid molecular DST that can detect resistance to the most common first and second line drugs with an approach that doesn't require sophisticated skills or laboratory equipment.6
The ideal test would support health care providers with the same quality of test results at the level of a reference lab as well as at decentralized healthcare facilities, to link more patients to appropriate care.
Xpert MTB/XDR allows fast molecular DST. Combined with the frontline test Xpert MTB/RIF Ultra, Xpert MTB/XDR sets new standards by detecting mutations associated with resistance towards isoniazid (INH), fluoroquinolones (FLQ), second-line injectable drug (SLID) (amikacin, kanamycin, capreomycin) and ethionamide (ETH) in a single test.
- Faster time to result for molecular DST
- Results in <90 minutes
- Same easy-to-use process as Xpert MTB/RIF Ultra
- Run on existing GeneXpert® platforms equipped with 10-color modules
(6) WHO. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. 2014